Exenatide was approved by the US FDA in 2005 and by the European Medicines Agency (EMA) in 2006
Lilly also reported diarrhea in 18.7%, 26.3%, and 22.8%, and vomiting in 15.7%, 15.0%, and 17.6% across the same retatrutide dose groups [9]
Vic chin rn hoc nu qu lu c th lm gim lng glutathione trong thc phm, lm tng cht bo khng bo ha v gy p lc cho h tiu ha
Acknowledgements We thank our colleagues for the critical reading of this manuscript, their valuable suggestions, as well as their useful comments for the preparation of this manuscript
This treatment can induce oxidative stress to the cells and, in turn, cause severe hemolysis in G6PD deficient patients
That can help us analyze incremental cost effectiveness